News of Note—CureVac, Bavarian Nordic and more

non
In this week's of news of note, CureVac's CEO is stepping down. (Pixabay)

Here is some other vaccine news of note for the week.

> Even a flu vaccine 20% effective would avert 21 million infections and save 61,000 lives, as long as about 40% of Americans got their shots, a new study led by Yale University researchers found. HealthDay News article

> CureVac’s founder and CEO Ingmar Hoerr, Ph.D., plans to transition to chairman, handing the reins over to current CBO and U.S. subsidiary CEO Daniel Menichella. Release

> Bavarian Nordic announced the FDA has granted orphan drug designation to its cancer vaccine BN-Brachyury for the treatment of chordoma. Release

> British firm Scancell raised £8.7 million in a public offering to help advance the development of its cancer vaccines. Labiotech article

The Scripps Research Institute landed a $12 million grant from the Bill & Melinda Gates Foundation to study vaccines that can neutralize many strains of malaria and influenza. Release

> Emergent BioSolutions reported $117.8 million in revenues from the first quarter, hurt by delays in the delivery of BioThrax and ACAM2000. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.